Brimonidine Tartrate

證據等級: L5

預測適應症: 0 個

---

目錄

1. Brimonidine Tartrate
2. Brimonidine Tartrate: Repurposing Evaluation — TxGNN Prediction Data Unavailable
   1. One-Sentence Summary
   2. Quick Overview
   3. Why This Prediction Cannot Yet Be Assessed
   4. Clinical Trial Evidence
   5. Literature Evidence
   6. Taiwan Market Information
   7. Safety Considerations
   8. Conclusion and Next Steps
   9. Disclaimer

---

## 藥師評估報告

Brimonidine Tartrate: Repurposing Evaluation — TxGNN Prediction Data Unavailable

One-Sentence Summary

Brimonidine Tartrate is an alpha-2 adrenergic agonist clinically established for reducing intraocular pressure in glaucoma and ocular hypertension. The current Evidence Pack contains no TxGNN-predicted new indications, and critical data fields — including MOA detail, safety warnings, and contraindications — are missing. A full repurposing evaluation cannot be completed at this stage; the report below documents what was retrieved and maps the remaining gaps.

---

Quick Overview

Item	Content
Original Indication	Glaucoma / Ocular Hypertension (established pharmacological class; not captured in this Evidence Pack)
Predicted New Indication	Not available — TxGNN prediction list is empty
TxGNN Prediction Score	Not available
Evidence Level	L5 — model prediction absent; no supporting studies identified
Taiwan Market Status	Not marketed (0 authorizations)
Number of Authorizations	0
Recommended Decision	Hold

---

Why This Prediction Cannot Yet Be Assessed

Brimonidine Tartrate belongs to the alpha-2 adrenergic agonist class. Its primary mechanism — selective stimulation of presynaptic and postsynaptic α₂-receptors — reduces aqueous humour production and increases uveoscleral outflow, thereby lowering intraocular pressure. Secondary mechanisms relevant to repurposing (neuroprotection via Bcl-2 upregulation, anti-inflammatory activity, vasoconstriction for dermatological applications such as rosacea) are documented in the literature but are absent from this Evidence Pack's original_moa field.

Without a populated predicted_indications array from TxGNN, it is not possible to assess mechanistic plausibility for any candidate new indication, nor to select supporting trials or publications. The pipeline appears to have retrieved a DrugBank record (query_log ID 3, status: success) and a TFDA package insert (query_log ID 4, status: success), but neither fed structured data into the Evidence Pack fields. This suggests a downstream parsing or mapping failure rather than a genuine absence of drug information.

---

Clinical Trial Evidence

Currently no TxGNN-predicted indication is available to scope a trial search. No clinical trial evidence can be presented.

---

Literature Evidence

Currently no TxGNN-predicted indication is available to scope a literature search. No publication evidence can be presented.

---

Taiwan Market Information

Brimonidine Tartrate holds zero TFDA authorizations. The drug is not marketed in Taiwan. No license table can be generated.

Note: Brimonidine is marketed under trade names such as Alphagan® and Mirvaso® in the US, EU, and multiple Asian markets. The TFDA query returned 0 results (query_log ID 1), which may reflect a formulation-specific or brand-name discrepancy rather than global non-approval. A cross-check against alternative spellings (e.g., "Brimonidine," "酒石酸溴莫尼定") is recommended.

---

Safety Considerations

All safety fields in this Evidence Pack are missing:

• Key warnings: not retrieved
• Contraindications: not retrieved
• Drug-drug interactions: query returned no results (query_log ID 2, status: not_found)

Please refer to the package insert (successfully retrieved per query_log ID 4) and DrugBank record (query_log ID 3) for warnings, contraindications, and interactions. These sources must be parsed and re-ingested before any safety evaluation can proceed.

Known class-level cautions for alpha-2 agonists include: cardiovascular depression, CNS sedation, rebound hypertension on abrupt withdrawal, and risk of severe hypotension when combined with antihypertensives or CNS depressants.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — TxGNN predictions are absent and two blocking data gaps (DG001: safety/warnings, DG002: MOA) remain unresolved. No repurposing hypothesis can be evaluated, and no safety review can be initiated, until these are resolved.

To proceed, the following is needed:

1. Re-run TxGNN inference for Brimonidine Tartrate and populate predicted_indications — confirm that the DrugBank entity ID is correctly mapped (DrugBank ID field is currently null).
2. Parse the TFDA package insert (already retrieved, query_log ID 4) to extract structured warnings and contraindications into safety.key_warnings and safety.contraindications.
3. Parse the DrugBank record (already retrieved, query_log ID 3) to extract original_moa, categories, and toxicity data.
4. Verify TFDA search coverage — re-query with simplified drug name ("Brimonidine") and Chinese INN ("溴莫尼定") to rule out zero-result artifacts.
5. Re-run DDI query once DrugBank ID is confirmed, as the current not_found status may stem from a missing identifier.
6. Once the above are resolved, regenerate the Evidence Pack and re-submit for a complete evaluation.

   Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---